MedPath

Endoceutics, Inc.

Endoceutics, Inc. logo
🇧🇪Belgium
Ownership
Holding
Established
2006-01-01
Employees
101
Market Cap
-
Website
http://www.endoceutics.com

Clinical Trials

9

Active:0
Completed:7

Trial Phases

1 Phases

Phase 3:9

Drug Approvals

1

EMA:1

Drug Approvals

Intrarosa

Authorization Status
Authorised
Approval Date
Jan 8, 2018
EMA

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 3
9 (100.0%)

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

Phase 3
Withdrawn
Conditions
Vaginal Atrophy in Breast Cancer Patients
Interventions
First Posted Date
2018-11-14
Last Posted Date
2020-07-31
Lead Sponsor
EndoCeutics Inc.
Registration Number
NCT03740945

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

Phase 3
Withdrawn
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
First Posted Date
2018-08-07
Last Posted Date
2020-07-31
Lead Sponsor
EndoCeutics Inc.
Registration Number
NCT03619005
Locations
🇺🇸

Endoceutics site # 106, Huntsville, Alabama, United States

🇺🇸

Endoceutics site # 17, San Diego, California, United States

🇺🇸

Endoceutics site # 125, New London, Connecticut, United States

and more 7 locations

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
First Posted Date
2017-09-19
Last Posted Date
2021-04-09
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
653
Registration Number
NCT03287232
Locations
🇺🇸

Endoceutics site # 106, Huntsville, Alabama, United States

🇺🇸

Endoceutics site # 104, Mobile, Alabama, United States

🇺🇸

Endoceutics site # 117, Tucson, Arizona, United States

and more 66 locations

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
First Posted Date
2013-12-17
Last Posted Date
2017-06-01
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
558
Registration Number
NCT02013544
Locations
🇺🇸

EndoCeutics site # 39, Montgomery, Alabama, United States

🇺🇸

EndoCeutics site # 14, Tucson, Arizona, United States

🇺🇸

EndoCeutics site # 21, Sacramento, California, United States

and more 35 locations

Topical DHEA Against Vaginal Atrophy

Phase 3
Completed
Conditions
Vaginal Atrophy
Interventions
First Posted Date
2013-05-03
Last Posted Date
2017-08-29
Lead Sponsor
EndoCeutics Inc.
Target Recruit Count
218
Registration Number
NCT01846442
Locations
🇺🇸

EndoCeutics site # 05, Cleveland, Ohio, United States

🇺🇸

EndoCeutics site # 03, Norfolk, Virginia, United States

🇨🇦

EndoCeutics site # 10, Montreal, Quebec, Canada

and more 5 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.